Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells
The concentration-dependent response of different ovarian cancer cell types to combination therapy confirms the need for in vitro optimization to maximize drug cytotoxicity. The OLL and TLL combination is a promising formulation for further animal studies, especially for eliminating epithelial ovarian cancer with wild-type BRCA1/2.
Authors
- Paulina Skupin-Mrugalska (ORCID: https://orcid.org/0000-0002-2495-6504)
- Olga B. Garbuzenko (ORCID: https://orcid.org/0000-0003-3685-7703)
- Arash Hatefi (ORCID: https://orcid.org/0000-0003-4611-7469)
- Aleksandra Romaniuk-Drapała (ORCID: https://orcid.org/0000-0002-3922-8729)
- Tamara Minko
Institutions
- Rutgers, The State University of New Jersey (US)
- Poznan University of Medical Sciences (PL)
- Rutgers Cancer Institute (US)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1186/s12935-024-03469-0
- Citations
- 11
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.11
Funders
- Weill Cornell Medical College